Efficacy and tolerability of intravenous levetiracetam in childrens.
- Additional Document Info
- View All
Intractable epilepsy in children poses a serious medical challenge. Acute repetitive seizures and status epilepticus leads to frequent emergency room visits and hospital admissions. Delay of treatment may lead to resistance to the first-line anticonvulsant therapies. It has been shown that these children continue to remain intractable even after acute seizure management with approved Food and Drug Administration (FDA) agents. Intravenous levetiracetam, a second-generation anticonvulsant was approved by the FDA in 2006 in patients 16 years and older as an alternative when oral treatment is not an option. Data have been published showing that intravenous levetiracetam is safe and efficacious, and can be used in an acute inpatient setting. This current review will discuss the recent data about the safety and tolerability of intravenous levetiracetam in children and neonates, and emphasize the need for a larger prospective multicenter trial to prove the efficacy of this agent in acute seizure management.
author list (cited authors)
Aceves, J., Khan, O., Mungall, D., Fonkem, E., Wright, C., Wenner, A., & Kirmani, B.
complete list of authors
Aceves, Jose||Khan, Owais||Mungall, Diana||Fonkem, Ekokobe||Wright, Chanin||Wenner, Andrea||Kirmani, Batool